Bedrijfsoverzicht
InspireMD, Inc. is a medical device company dedicated to the development and commercialization of products designed for the treatment of carotid artery disease and other vascular conditions. The company operates within the healthcare sector, specifically in the medical devices industry, which implies a focus on specialized equipment and technologies used in clinical settings across the United States, Germany, Italy, Russia, Poland, and international markets. This specialized focus requires rigorous regulatory compliance and substantial R&D investment to maintain product efficacy and safety standards. The company currently holds a market capitalization of $60.37M and reports annual revenue (TTM) of $8.98M, employing a workforce of 127 individuals to execute its operational strategy. These valuation and revenue figures indicate that InspireMD operates as a small-cap entity with a market presence significantly below the major industry leaders, suggesting it is in a growth or development phase rather than a mature market dominance stage. The relatively modest revenue base of $8.98M supports the employee count of 127, highlighting the labor-intensive nature of medical device development and commercialization at this stage of the company's lifecycle.
Financiële gezondheid
The company's financial performance for the trailing twelve months shows a revenue of $8.98M, contrasted sharply by a net income of $-48,786,000 and an EBITDA of $-49,138,000. The substantial negative net income relative to positive revenue reveals a cost structure characterized by high operating expenses, likely driven by research and development costs, manufacturing overhead, and general administrative expenses that currently exceed gross profits. Free cash flow stands at $-18,728,750, which indicates that the company is burning cash to fund its operations and growth initiatives, thereby limiting its immediate financial flexibility and reliance on external capital sources. The gross margin is reported at 29.5%, suggesting that the company retains nearly 30 cents for every dollar of revenue after covering the direct costs of goods sold, which is a reasonable but not exceptional figure for the medical device sector. In contrast, the operating margin is significantly negative at -383.7%, and the profit margin is 0.0%, indicating that overhead costs are consuming all operating income and leaving no room for net profitability at this time. On the balance sheet, the company holds $54.21M in cash against $3.29M in debt, resulting in a debt-to-equity ratio of 5.96, which suggests a highly leveraged position where equity capital is low relative to debt obligations. However, the current ratio of 5.74 demonstrates strong short-term liquidity, as the company holds more than five times the current liabilities in liquid assets, providing a buffer against immediate repayment needs. Return on Equity is -106.9% and Return on Assets is -53.4%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and utilized in assets due to the losses incurred during this period.
Waarderingsbeoordeling
The valuation metrics present a complex picture given the lack of positive earnings, with a trailing P/E ratio of N/A and a forward P/E of -2.13. The difference between the non-existent trailing P/E and the negative forward P/E implies that the market is pricing in a potential turnaround or restructuring, as standard earnings-based multiples are not applicable due to current losses. The price-to-book ratio is 1.02, which indicates that the market values the company's equity at essentially one dollar for every dollar of its book value, suggesting no significant market premium over the net asset value. Alternative valuation metrics such as the price-to-sales ratio of 6.72 and the EV/EBITDA of -0.19 provide further context, suggesting that investors are valuing the company primarily on its revenue generation potential rather than current profitability or earnings power. Regarding trading range, the 52-week high is $2.93 and the 52-week low is $1.28, meaning the current price sits within this historical range but requires calculation to determine the exact percentage distance from the highs and lows without specific current price data provided in the facts. The beta value of 0.94 indicates that the stock's price volatility is roughly in line with the broader market, moving slightly less aggressively than the S&P 500 during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is reported at 61.6%, while earnings growth is N/A due to the company's current unprofitable status. The fact that earnings growth is not applicable while revenue is growing rapidly implies that the company is still in the investment phase where top-line expansion is prioritized over bottom-line profitability. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders. Instead, the company reinvests its earnings, or rather its cash reserves, into growth initiatives such as product development, market expansion, and operational scaling rather than paying dividends. The overall growth and income profile characterizes InspireMD as a high-growth, non-dividend paying entity that relies on capital appreciation and future profitability to generate returns for investors rather than current cash distributions or stable earnings growth.